Cas:286840-92-4 2-(2,6-dichlorophenoxy)-3-(dimethylamino)prop-2-enal manufacturer & supplier

We serve Chemical Name:2-(2,6-dichlorophenoxy)-3-(dimethylamino)prop-2-enal CAS:286840-92-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-(2,6-dichlorophenoxy)-3-(dimethylamino)prop-2-enal

Chemical Name:2-(2,6-dichlorophenoxy)-3-(dimethylamino)prop-2-enal
CAS.NO:286840-92-4
Synonyms:2-Propenal,2-(2,6-dichlorophenoxy)-3-(dimethylamino);2-(2,6-dichlorophenoxy)-3-(dimethylamino)acrylaldehyde
Molecular Formula:C11H11Cl2NO2
Molecular Weight:260.11700
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:29.54000
Exact Mass:259.01700
LogP:2.97410

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2-Propenal,2-(2,6-dichlorophenoxy)-3-(dimethylamino) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(2,6-dichlorophenoxy)-3-(dimethylamino)acrylaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Propenal,2-(2,6-dichlorophenoxy)-3-(dimethylamino) Use and application,2-Propenal,2-(2,6-dichlorophenoxy)-3-(dimethylamino) technical grade,usp/ep/jp grade.


Related News: In Massachusetts, where the bulk of Takeda’s U.S. operations are based since the Shire buyout, the Japanese pharma has been swiftly ramping up its cell therapy ambitions. In September, the company cut the ribbon on a new 24,000-square-foot R&D manufacturing center in Boston, which it said at the time would handle clinical development for three ongoing pipeline programs and two other prospects pegged to enter clinical development by the end of 2021. N-(2-phenylethylcarbonyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid manufacturers The Company’s Family 1 includes patent-pending compounds comprising two patent applications with priority dates of February 2020. 5-(3-phenylpropionamidomethyl)-6-chloro-3-(1-methyl-2-(R)-azetidinyl-methoxy)pyridine suppliers In the Phase III VICTORIA study, Verquvo met the primary efficacy objective based on a time-to-event analysis. 1-(Bromo-dimethyl-silanyl)-2-(chloromethyl-dimethyl-silanyl)-ethyne vendor & factory.